# The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

> **NCT06851403** · — · ENROLLING_BY_INVITATION · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 213 (estimated)

## Conditions studied

- Asthma in Children

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06851403
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-01-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851403, "The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06851403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*